Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes

Inclusion Criteria: * Type 1 diabetes for at least 12 months * Serum C-peptide maximum 0.4 ng/mL * Current basal bolus treatment with soluble human insulin, insulin lispro, insulin glulisine, NPH insulin, insulin detemir or insulin glargine * BMI (Body Mass Index) maximum 32 kg/m\^2 * HbA1c (glycosylated haemoglobin) maximum 9% based on analysis from central laboratory * Non-smoker Exclusion Criteria: * The receipt of any investigational drug within the last 30 days prior to this trial * Total daily insulin dose at least 1.8 U/kg/day * Current treatment with IAsp (insulin aspart) products * A history of drug or alcohol abuse within the last 5 years * Impaired hepatic function * Impaired renal function * Cardiac problems * Severe, uncontrolled hypertension